Acute myeloid leukemia (AML) has highly heterogeneous clinical manifestations and poor prognosis, and traditional chemotherapy is the main treatment. In recent years, with the in-depth development of next-generation sequencing technology, the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype. The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML. Compared with traditional chemotherapy, targeted therapy has the advantages of significant curative effect and fewer adverse effects. This article reviews the latest research progress of targeted drug therapy for AML.
题目: 急性髓系白血病靶向治疗进展.
摘要: .急性髓系白血病（AML）临床表现具有高度异质性，预后差，治疗以传统化疗为主。近年来，随着二代测序技术的深入发展，AML的治疗逐渐向分子生物学和免疫表型方向的精准靶向治疗发展，各种小分子抑制剂、免疫靶向药物等的问世为不能耐受强化疗和复发难治AML患者带来了希望。相较于传统化疗，靶向治疗具有疗效显著、副作用少等优点，现就AML靶向药物治疗最新研究进展作一综述。.
Keywords: acute myeloid leukemia; chimeric antigen receptor T cell; targeted therapy; antibody-drug conjugate.